Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9475 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Apr 1, 2016 In Use
J9352 Trabectedin Yondelis 0.1mg Chemotherapy Alkylating Agent Natural Product No 2015 Jan 1, 2017 In Use
NA Palbociclib Ibrance 75 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA Palbociclib Ibrance 125 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA Palbociclib Ibrance 100 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA ixazomib Ninlaro 2.3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA Dinutuximab Unituxin 3.5 mg/mL Immunotherapy Monoclonal Antibody GD-2 No 2015 In Use
C9476 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jul 1, 2016 In Use
NA Uridine Triacetate Vistogard 10 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
J1447 Tbo-filgrastim Granix 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2015 Jan 1, 2016 In Use
NA lenvatinib Lenvima 10 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET Yes 2015 In Use
NA Uridine Triacetate Xuriden 2 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
J8565 Gefitinib Iressa 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2015 Jan 1, 2005 In Use
NA ixazomib Ninlaro 3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA Trifluridine and Tipiracil Lonsurf 15/6.14 mg Chemotherapy Antimetabolite Pyrimidine Analog Yes 2015 In Use
NA lenvatinib Lenvima 4 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET Yes 2015 In Use
NA Panobinostat Farydak 20 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Osimertinib Tagrisso 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2015 In Use
J9176 Elotuzumab Empliciti 1 mg Immunotherapy Monoclonal Antibody SLAMF7 No 2015 Jan 1, 2017 In Use
J9295 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Jan 1, 2017 In Use
NA Panobinostat Farydak 15 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Osimertinib Tagrisso 80 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2015 In Use
NA sonidegib odozmo 200 mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2015 In Use
J9325 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Jan 1, 2017 In Use
NA venetoclax Venclexta 10 mg Chemotherapy Enzyme Inhibitor BCL-2 Yes 2016 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.